Simulations Plus, Inc. (SLP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

At the Morgan Stanley Global Healthcare Conference, Simulations Plus (SLP) CEO Shawn O'Connor detailed the company's 30-year history in biosimulation, providing "in silico models" that accelerate drug development timelines and enhance efficiency. These solutions span from early discovery and lead optimization through clinical trials and post-approval applications, including support for bioequivalence waivers and formulation changes, underscoring the increasing industry acceptance of biosimulation technology.

Analysis

At the Morgan Stanley Global Healthcare Conference, Simulations Plus (SLP) CEO Shawn O'Connor reinforced the company's established position as a 30-year veteran in the biosimulation market. The presentation highlighted that SLP's platform of 'in silico models' provides tangible efficiencies and accelerates timelines across the entire drug development lifecycle, from early-stage discovery through all clinical phases and into post-approval. A key value driver is the platform's application in securing bioequivalence waivers and supporting formulation changes, which can eliminate the need for costly and time-consuming clinical trials. According to the CEO, this comprehensive utility is driving increased acceptance of biosimulation from scientific, sponsor, and regulatory perspectives, solidifying its role as an integral component of modern pharmaceutical development.

Key Decisions for Investors

• The CEO's commentary reinforces the long-term bullish thesis for SLP, positioning the company as an established leader in the growing biosimulation market which is integral to improving drug development efficiency.
• Investors should recognize the company's comprehensive, end-to-end platform as a significant competitive advantage, as its application from discovery to post-approval creates a deeply integrated and sticky service offering.
• Consider monitoring for further evidence of industry and regulatory adoption of biosimulation, as broader acceptance for applications like bioequivalence waivers is a primary catalyst for the company's continued growth.